• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biotech loses pioneer Henri Termeer

Biotech loses pioneer Henri Termeer

May 15, 2017
CenterWatch Staff

Friday, May 12th, Genzyme founder Henri Termeer passed at age 71.

Termeer led Genzyme of almost 30 years. He rose to CEO shortly before its acquisition by Sanofi in 2011. Many in the industry credit Termeer with developing a business model that widened possibilities for rare and orphan therapies.

In 2011, he seeded the startup Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital with a $10 million donation.

After leaving Genzyme, Termeer sat on the board for companies including Abiomed, Aveo Pharma, Moderna Therapeutics and Verastem. He also played a key role in the foundation of Cambridge-based health policy company the Network for Excellence in Health Innovation.

As said to FierceBiotch, Bob Coughlin, president of the Massachusetts Biotechnology Council, said that Termeer was "one of the founders of the modern biotech industry" and had "changed the lives of patients around the world through his ongoing dedication to discovering breakthrough treatments for those with rare diseases."

In an interview with The Boston Business Journal, Josh Boger, founding CEO of Vertex Pharmaceuticals, said that Termeer has served as his example for how to run a biotech firm since the early 1990s. Boger credited Termeer with his decision to serve as chairman of BIO, beginning in 2007.

The World Orphan Drug Congress said, "Henri was a biotech pioneer long before anyone knew what biotechs were. He founded Genzyme, which is often said to have kickstarted today’s orphan drug biotech M&A frenzy. Henri is definitely a mover/shaker in the biotech world and in the orphan drug space. He will always be known as the guy who figured out how to build a great business by making drugs for rare diseases. An inspiration and pioneer, many of his protégés have since moved on to lead other successful companies in the rare disease and biotech space thanks to his influence."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing